Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

V1RD17 Inhibitors

V1RD17 inhibitors are a class of chemical compounds that interact with a specific biochemical pathway by targeting a molecule known as V1RD17. This molecule plays a crucial role in a particular biological process, and the inhibitors are designed to bind to V1RD17 and alter its normal function. The action of these inhibitors hinges on their ability to fit into the active site or another significant binding region of the V1RD17 molecule, which leads to the modulation of its activity. This modulation can either increase or decrease the activity of the V1RD17, depending on the nature of the inhibitor and the specific context of its interaction with the molecular target.

The structure of V1RD17 inhibitors is often complex, owing to the need for a high degree of specificity in their interaction with V1RD17. The design of these compounds takes into account the three-dimensional shape of the V1RD17 molecule, as well as the electronic and chemical properties of its active site. This often involves a detailed understanding of the biochemistry involved in the V1RD17 pathway, including the types of bonds that can be formed or broken and the steric considerations that dictate how the inhibitor can approach and interact with V1RD17. The development of V1RD17 inhibitors typically requires a multi-disciplinary approach that includes elements of organic chemistry, molecular biology, computational modeling, and various types of spectroscopy and crystallography to determine the structure of the target molecule and the best way to influence its activity.

SEE ALSO...

Items 11 to 12 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. If V1RD17 activity is associated with EGFR signaling, gefitinib would result in decreased V1RD17 function by blocking the phosphorylation and activation of EGFR and its downstream signaling cascades.

BML-275

866405-64-3sc-200689
sc-200689A
5 mg
25 mg
$96.00
$355.00
69
(1)

An inhibitor of the BMP signaling pathway by selectively inhibiting the BMP type I receptors ALK2, ALK3, and ALK6. If V1RD17 function is mediated through BMP signaling, dorsomorphin would lead to a decrease in V1RD17 activity by preventing phosphorylation and activation of SMAD1/5/8 and BMP-specific gene expression.